Beta Cell Mass in Type 2 DM Gepts et al McClean et al Westermark et al Saito et al Stefan et al Ann Roy Sci Med Nat 10:1, 1957 Reduced Diabetes 4:367,

Slides:

Advertisements

Similar presentations

Inside the Islet Exploring Issues in Type 2 Diabetes Role of Pancreatic Islets in Maintaining Normal Glucose Homeostasis.

Advertisements

Current Management of Type 1 and Type 2 Diabetes Thomas Donner, M.D. Division of Endocrinology & Metabolism.

Jaime A. Davidson, MD, FACP, MACE

What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.

Pathophysiology of Type 1 Diabetes

Recovery of the β–cell function both in new and long-standing type 2 diabetic patients through long-term treatment with continuous subcutaneous insulin.

Treating Earlier and Effectively with Combination Therapies.

The Diagnosis of Diabetes Mellitus

1 The Burden of Type 1 Diabetes. 2 Incidence and Prevalence of Type 1 Diabetes Type 1 diabetes mellitus (T1DM) is the major type of diabetes in youth.

Conditions associated with insulin resistance

Caloric Restriction and Resveratrol Reverse a High-fat Diet Induced Diabetes and Improve Islet β cell Dysfunction in Mice Jiaoyue Zhang Ph.D Endocrinology.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.

Insulin Pump Debrief. Now that you have worn a Pump… FAQ from people with diabetes Where do I wear this thing? What do I do with it when I play sports?

Pathophysiology of Type 1 Diabetes 1. Type 1 Diabetes Mellitus Characterized by absolute insulin deficiency Pathophysiology and etiology –Result of pancreatic.

in the pancreatic beta-cell

Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 1.

Type 2 diabetes Derek LeRoith. Insulin Resistance: A Core Defect of The Metabolic Syndrome Insulin Resistance Dyslipidemia Obesity Hypertension Dysfibrinolysis.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 3 of 5.

Natural History of Type 2 Diabetes Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota. ObesityIFG*DiabetesUncontrolled Hyperglycemia.

An initiative of South Asian Federation of Endocrine Societies (SAFES)

Co-Mentors Dr. Melissa Brown, Phd, RD Dr. Alan Schneyer, Phd.

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?

In T2DM, β-Cell Mass in Islets is Significantly Reduced

Fig. 1. Time line for investigations

Pathophysiology of Type 1 Diabetes

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Nat. Rev. Endocrinol. doi: /nrendo

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Pushback What about ‘pure’ Insulin Resistance Syndromes?

Graph of interaction for study of insulin sensitivity

CV Risk of SU and Insulin

Figure 2 Pathophysiology of hyperglycaemia in T2DM

Type 1 Diabetes Mellitus

תכולת האינסולין בלבלבי מודל חולדות כהן סוכרתיות

Diabetes and Bone: the model of GIO

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Nephrol. doi: /nrneph

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Diet, Obesity, and Chronic Disease

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Nat. Rev. Endocrinol. doi: /nrendo

b cell mass and regeneration

Fig Reduced beta cell mass in type 2 diabetic patients, as compared to non-diabetic controls, although there is a marked inter-subject variability.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

HOMA calculations where glucose is mmol/L and insulin is mU/L

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Carbohydrate absorption inhibitors α-glucosidose inhibitors

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Incretin Physiology in Type 2 Diabetes Mellitus

Glycemia and glucose tolerance of RIP-N mice.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Comparison of the regression lines for AIRarg (the acute insulin response to intravenous arginine over 2–5 min after injection) and AIRargMAX (the response.

Zn2+ and NAD(P)H content in Mafa∆panc and Mafa∆panc;Mafb+/− β-cells.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Beta Cell Mass in Type 2 DM Gepts et al McClean et al Westermark et al Saito et al Stefan et al Ann Roy Sci Med Nat 10:1, 1957 Reduced Diabetes 4:367, 1957Reduced Diabetologia 15:417, 1978Reduced Tokohu J Exp Med 129:273, 1979Reduced Diabetes 31:694, 1982Reduced Kloppel et alSurv Synth Path Res 4:110, 1985Reduced Clark et alDiabetes Res Clin Prac 4:151, 1988Reduced Guiot et alDiabetes 50 (Suppl 1):S188, 2001Reduced Sakuraba et alDiabetologia 45:85, 2002Reduced Butler et alDiabetes 52:102, 2003Reduced Voon et alJ Clin Endocrinol Metab 88:2000,2003Reduced Rahier et alDiab Obes Metab Suppl 4:32, 2008Reduced

35%  -cells 65% β-cells 52%  -cells 48% β-cells P <0.01 Adapted from Deng S, et al. Diabetes. 2004;53: T2DMControl In T2DM, β-Cell Mass in Islets is Significantly Reduced

Beta cell mass is a function of relative rates of apoptosis, replication and neogenesis.

Butler et al Diabetes 52:102, 2003

Pathogenesis of Type 2 Diabetes Beta Cell Mass and Function NormalAbnormal Insulin Resistance Yes No Normal Glucose ToleranceAbnormal Glucose Tolerance Deterioration in Capacity to Secrete Insulin Glucose-Lipotoxicity Loss of Mass Type 2 Diabetes Compensation ++